The ER+/ HER2 -ve Breast Cancer market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
ER+/ HER2 -ve Breast Cancer: An Overview
Breast Cancer initiates when abnormal cancerous cells in the breast grow and multiply without stopping, creating a tumor. It usually starts in the ducts or lobules of the breast. Cancer cells get many signals that drive their growth. These signals may take the form of hormones.
Hormone receptors are proteins that receive hormone signals and tell the cancer cells to grow. If Breast Cancer cells get signals from the hormone estrogen that could promote tumor growth, it is known as estrogen receptor-positive (ER+) Breast Cancer. If cancerous cells get signals from the hormone progesterone that could promote growth, it is known as progesterone receptor-positive (PR+) Breast Cancer. Breast Cancer that is ER+ or PR+ falls under the category of hormone receptor-positive (HR+) Breast Cancer.
In HER2−negative, cancer cells do not have a high amount of a protein called HER2 on their surface. Cancer cells that are HER2 negative may grow more slowly and are less likely to recur (come back) or spread to other parts of the body than cancer cells that have a large amount of HER2 on their surface. Checking for HER2 on some types of cancer cells may help plan treatment.
ER+/ HER2 -ve Breast Cancer Market Key Facts
-
The total market size of ER+/HER2− Breast Cancer in the United States is USD 6,759 million in 2021 and is projected to grow during the forecast period (2022-2032)
-
The total market size of ER+/HER2− Breast Cancer in the first-line setting in the United States was USD 3,471 million in 2021
-
The total incident population of Breast Cancer in the United States was 256,000+ in 2021.
-
Among the various subtypes of the disease (localized and regional), ER+/HER2− occupies the maximum patient pool, with 147,900+ cases of this category, followed by the number of those with 24,300+ cases of Triple-negative and 20,200+ cases of ER+/HER2+. On the other hand, HR−/HER2+ accommodated the least number of cases.
ER+/ HER2 -ve Breast Cancer Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted ER+/ HER2 -ve Breast Cancer market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the ER+/ HER2 -ve Breast Cancer market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
ER+/ HER2 -ve Breast Cancer Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
ER+/ HER2 -ve Breast Cancer Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the ER+/ HER2 -ve Breast Cancer market or expected to be launched during the study period. The analysis covers the ER+/ HER2 -ve Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the ER+/ HER2 -ve Breast Cancer pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the ER+/ HER2 -ve Breast Cancer Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-market
ER+/ HER2 -ve Breast Cancer Therapeutics Analysis
Several major pharma and biotech giants are developing ER+/ HER2-VE Breast Cancer therapies. Currently, AstraZeneca is leading the therapeutics market with its ER+/ HER2-VE Breast Cancer drug candidates in the most advanced stage of clinical development.
The Leading Companies in the ER+/ HER2 -ve Breast Cancer Therapeutics Market Include:
-
AstraZeneca
-
BeiGene
-
CytomX Therapeutics
-
Daiichi Sankyo
-
Eli Lilly
-
EQRx
-
Evgen Pharma
-
G1 Therapeutics
-
Genentech
-
Gilead
-
H3 Biomedicine
-
Jiangsu HengRui Medicine
-
Olema Pharmaceuticals
-
Radius Pharmaceuticals
-
Roche
-
Sanofi
-
Sermonix Pharmaceuticals
-
Tyme
-
Veru
And Many More
ER+/ HER2 -ve Breast Cancer Therapies Covered in the Report Include:
-
BGB-290: BeiGene
-
Camizestrant (AZD9833): AstraZeneca
-
Elacestrant: Radius Pharmaceuticals
-
Giredestrant (RG6171, GDC-9545): Roche
-
Lerociclib (EQ132): EQRx
-
LY3484356 (imlunestrant): Eli Lilly
And Many Others
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. ER+/ HER2 -ve Breast Cancer Competitive Intelligence Analysis
4. ER+/ HER2 -ve Breast Cancer Market Overview at a Glance
5. ER+/ HER2 -ve Breast Cancer Disease Background and Overview
6. ER+/ HER2 -ve Breast Cancer Patient Journey
7. ER+/ HER2 -ve Breast Cancer Epidemiology and Patient Population (In the US, EU5, and Japan)
8. ER+/ HER2 -ve Breast Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. ER+/ HER2 -ve Breast Cancer Unmet Needs
10. Key Endpoints of ER+/ HER2 -ve Breast Cancer Treatment
11. ER+/ HER2 -ve Breast Cancer Marketed Products
12. ER+/ HER2 -ve Breast Cancer Emerging Drugs and Latest Therapeutic Advances
13. ER+/ HER2 -ve Breast Cancer Seven Major Market Analysis
14. Attribute Analysis
15. ER+/ HER2 -ve Breast Cancer Market Outlook (In US, EU5, and Japan)
16. ER+/ HER2 -ve Breast Cancer Access and Reimbursement Overview
17. KOL Views on the ER+/ HER2 -ve Breast Cancer Market
18. ER+/ HER2 -ve Breast Cancer Market Drivers
19. ER+/ HER2 -ve Breast Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-market
Other Trending Healthcare Reports By DelveInsight
ER+/ HER2 -ve Breast Cancer Pipeline Insight
“ER+/ HER2-VE Breast Cancer – Pipeline Insight, 2023,” report provides comprehensive insights about 40+ companies and 50+ drugs in ER+/ HER2-VE Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by type, stage, route of administration, and molecule type.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/